Statin on insulin and adiponectin levels: true or false prophecy?

Jonnalagadda, Venu Gopal; Shaik, Afsar

doi:10.2147/dmso.s160853

Cited by 2 publications

(2 citation statements)

References 4 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF is regarded as key factor in the development of ALI and ARDS through induction of vascular permeability. VEGF serum levels were illustrated to be higher in patients with severe COVID-19 compared with the mild one [ 74 , 75 ]. SARS-CoV-2 infection-induced down-regulation of ACE2 is considered as the main cause for overexpression of VEGF.…”

Section: Fenofibrate and Covid-19mentioning

confidence: 99%

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

et al. 2022

View full text Add to dashboard Cite

Introduction Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties. Fenofibrate is effective against a variety of viral infections and different inflammatory disorders. Therefore, the aim of critical review was to overview the potential role of fenofibrate in the pathogenesis of SARS-CoV-2 and related complications. Results By destabilizing SARS-CoV-2 spike protein and preventing it from binding angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV-2 entry, fenofibrate can reduce SARS-CoV-2 entry in human cells Fenofibrate also suppresses inflammatory signaling pathways, which decreases SARS-CoV-2 infection-related inflammatory alterations. In conclusion, fenofibrate anti-inflammatory, antioxidant, and antithrombotic capabilities may help to minimize the inflammatory and thrombotic consequences associated with SARSCoV-2 infection. Through attenuating the interaction between SARS-CoV-2 and ACE2, fenofibrate can directly reduce the risk of SARS-CoV-2 infection. Conclusions As a result, fenofibrate could be a potential treatment approach for COVID-19 control.

show abstract

Section: Fenofibrate and Covid-19mentioning

confidence: 99%

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

et al. 2022

View full text Add to dashboard Cite

show abstract

“…15 Liver damage is caused by a variety of pathogenic factors, such as oxidative stress, immune reactions, hepatitis viruses, ethanol, drugs, and various toxic substances. [16][17][18][19][20] This damage can progress to liver brosis and cirrhosis. 21,22 An accumulation of free radicals is an important pathogenic mechanism leading to liver injury.…”

Section: Introductionmentioning

confidence: 99%

Antioxidant activities of anastatin A & B derivatives and compound 38c's protective effect in a mouse model of CCl₄-induced acute liver injury

et al. 2020

View full text Add to dashboard Cite

show abstract

Statin on insulin and adiponectin levels: true or false prophecy?

Cited by 2 publications

References 4 publications

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

Antioxidant activities of anastatin A & B derivatives and compound 38c's protective effect in a mouse model of CCl₄-induced acute liver injury

Contact Info

Product

Resources

About

Statin on insulin and adiponectin levels: true or false prophecy?

Cited by 2 publications

References 4 publications

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

Antioxidant activities of anastatin A & B derivatives and compound 38c's protective effect in a mouse model of CCl4-induced acute liver injury

Contact Info

Product

Resources

About

Antioxidant activities of anastatin A & B derivatives and compound 38c's protective effect in a mouse model of CCl₄-induced acute liver injury